Synagis 50 mg

SYNAGIS 50 MG is a solution containing palivizumab, used for respiratory syncytial virus (RSV) prevention. This intramuscular injection is manufactured by AstraZeneca Canada Inc.

SYNAGIS 50 MG is primarily used for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk infants and children. Palivizumab, the active ingredient, is designed to help reduce the risk of RSV-related hospitalizations. This medication is often recommended for use during RSV season or for those with a history of severe RSV infections.

Common effects of SYNAGIS 50 MG may include mild reactions at the injection site, such as redness or swelling. Some individuals might experience fever or irritability following administration. These effects are generally mild and temporary.

SYNAGIS 50 MG should be administered by healthcare professionals experienced in intramuscular injections. It is important to inform your healthcare provider about any allergies or medical conditions before use. Always follow the prescribed guidelines for storage and handling to maintain the medication's efficacy.

SYNAGIS 50 MG may interact with other medications, so it is crucial to discuss all current treatments with your healthcare provider. Specific interactions with palivizumab are not well-documented, but caution is advised when combining with other immunosuppressive therapies.